Authors
Latest:
Unmet Needs and Future Directions in Care in CLLClosing out their discussion on novel treatment strategies in CLL, expert hematologist-oncologists address unmet needs and future directions in care.
Latest:
Dr Smith on Bispecific Antibodies for the Management of R/R Follicular LymphomaSonali M. Smith, MD, discusses the current arsenal of bispecific antibodies available for the management of relapsed/refractory follicular lymphoma.
Latest:
Updates on Multiple Myeloma Diagnosis and Treatment StrategiesProgress in our understanding of multiple myeloma pathogenesis has led to the identification of new therapeutic targets.
Latest:
Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLCSonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.
Latest:
Dr. Fosså on Radiotherapy/ Antiandrogen TherapySophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, discusses a trial analyzing the benefit for radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.
Latest:
Dr. Papa on Leukapheresis Manufacturing Approach in Head and Neck CancerSophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses leukapheresis manufacturing approach in head and neck cancer.
Latest:
Reflections of a Growing OncologistWhile providing information on the cancer and treatment gets a little easier with time, empathizing and accepting the emotions that patients and their families express does not.
Latest:
ASCO: New data for Alecensa shows 5-year overall survival in ALK-positive NSCLCOn Friday 29 May at the ASCO20 Virtual Scientific Programme, Roche presented updated data from the pivotal phase III ALEX clinical study.
Latest:
ESMO Data Show More Can Be Done for Cancer of Unknown Primary PatientsTwo research papers presented by Roche and Foundation Medicine at the 2019 European Society of Medical Oncology (ESMO) Annual Meeting demonstrate both the promise of an innovative precision medicine driven clinical trial for patients with cancer of unknown primary, as well as the challenges of identifying eligible patients for the trial, according to ESMO guidelines.
Latest:
Biosimilars in Cancer Care: Potentially Improving Patient Access to Essential Therapies9,10Gary Fanjiang, MD, vice president of Biosimilars Global Development, Amgen, discusses the development of biosimilars and some of the clinical considerations related to their use.
Latest:
TIL Therapy May Provide Second-Line Option for Cervical CancerInvestigators are optimistic that LN-145, an autologous tumor-infiltrating lymphocyte investigational therapy, could be a potential treatment option for patients with recurrent, metastatic, or persistent cervical cancer.
Latest:
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Offers Subcutaneous CD38-Directed Antibody to Health Care Providers and Their Multiple Myeloma PatientsSince the U.S. Food and Drug Administration (FDA) approval of DARZALEX® (daratumumab) in 2015, the first CD38-directed antibody to treat multiple myeloma has been used in the treatment of more than 68,000 patients in the U.S. alone.
Latest:
Targeted Treatment Helps Delay ALK+ mNSCLC ProgressionRemarkable progress has been made in the treatment of ALK+ mNSCLC patients, and the field continues to grow at a rapid pace.
Latest:
Dr. Aithal on the HERceptin Adjuvant (HERA) TrialSramila Aithal, MD, from Cancer Treatment Centers of America, discusses the HERceptin Adjuvant (HERA) trial that examined adjuvant therapy with trastuzumab for women with HER2-positive early breast cancer.
Latest:
Dr. Verstovsek on the Potential Role of Rusfertide in Polycythemia VeraSrdan Verstovsek, MD, PhD, discusses the potential for rusfertide in polycythemia vera.
Latest:
PERSIST-1 and PERSIST-2 Trials in MyelofibrosisExpert hematologist/oncologists review the use of pacritinib for the treatment of myelofibrosis, as seen in the PERSIST-1 and PERSIST-2 trials.
Latest:
Bone Marrow Transplant for Patients With MFExpert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.
Latest:
Dr. Chittoor on Targetable Mutations and Respective Treatments in NSCLCSreeni Chittoor, MD, FACP, discusses targetable mutations and respective treatment options for patients with metastatic non–small cell lung cancer.
Latest:
Dr. Ramaswamy Discusses Tumor HeterogeneityDr. Sridhar Ramaswamy from the Massachusetts General Hospital Cancer Center Discusses Tumor Heterogeneity
Latest:
Dr. Sridhar on Nab-Paclitaxel in Urothelial CancerSrikala Sridhar, MD, MSc, from the University of Toronto, Canada, discusses the results of a single arm phase II trial examining nab-paclitaxel as a secondary treatment for urothelial cancer.
Latest:
Colorectal Cancer: Right Test, Right TimeColorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease, with molecular features defining emerging subtypes. Understanding which tests to order in which cases can better direct care for our patients. Increasingly, panel testing has advantages over individual genetic testing.
Latest:
Dr. Levine on Palliative Care for NSCLCStacie Levine, MD, associate professor of Medicine, director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, University of Chicago Medicine, discusses the benefits of palliative care for patients with non–small cell lung cancer (NSCLC).
Latest:
Dr. Loeb on the Impact of Additional Testing for Prostate CancerStacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses the impact of different genomic tests for patients with prostate cancer.
